Woman’s brain tumor shrinking after poliovirus injection

 
 
Duke Cancer Center MRI technician Miguel Rosario, right, adjusts a set of headphones for brain cancer patient Stephanie Lipscomb, 22, at the start of a 20-minute MRI scan series on a large Siemens 3 tesla scanner at Duke Cancer Center, July 15, 2013, in Durham, North Carolina. (Harry Lynch/Raleigh News & Observer/MCT)
Duke Cancer Center MRI technician Miguel Rosario, right, adjusts a set of headphones for brain cancer patient Stephanie Lipscomb, 22, at the start of a 20-minute MRI scan series on a large Siemens 3 tesla scanner at Duke Cancer Center, July 15, 2013, in Durham, North Carolina. (Harry Lynch/Raleigh News & Observer/MCT)
HARRY LYNCH / MCT

The News & Observer (Raleigh, N.C.)

The same virus that causes paralysis and sometimes death in polio patients may have the potential to cure people with cancerous brain tumors based on early results of a research trial underway at Duke University Medical Center.

Stephanie Lipscomb, 22, learned that she was nearly cancer-free during a recent checkup at Duke Cancer Center, 14 months after a modified version of the poliovirus was injected into her brain to treat a recurring, aggressive cancer known as glioblastoma.

“I’m really pleased; the nodule is almost all gone,” neuro-oncologist Annick Desjardins told Lipscomb.

Lipscomb became the first patient to enter the first phase of testing for the poliovirus-based therapy when she was given the virus through a catheter inserted into her brain in May 2012.

“The fact that this patient had the procedure 14 months ago and there’s been no regrowth of the tumor is very, very exciting and promising,” said Desjardins, lead investigator in the study.

So far, seven patients have been treated in the poliovirus study. Two who joined the project shortly after Lipscomb also have experienced dramatic shrinkage of their tumors, while two others failed to improve. An additional two patients have been treated more recently, and doctors say it is too early to determine the results.

The glioblastoma treatment uses the Sabin 1 virus strain developed in the 1950s to vaccinate humans against polio disease.To ensure greater safety, researchers altered the virus so it could not grow in normal brain cells, said Matthais Gromeier, a polio-virologist at Duke who developed the therapy.

The modified virus has been tested in both primates and humans over the past decade, Gromeier said.

“We have tested it with a sufficient amount of patients to know it is absolutely safe in humans,” he said. “We have not observed any toxic side effects.”

Exactly how the poliovirus works against cancer cells is still being studied, but Gromeier thinks it triggers a response in the patient’s immune system.

“Since we are all vaccinated against polio, we already have immune defenses,” he said. “So when we infect the tumor, our immune system will come in and respond and turn against the patient’s tumor.”

The poliovirus is among a number of viral agents being studied in cancer research, said Jan Buckner, chairman of the Department of Oncology at Mayo Clinic in Rochester, Minn., who heard a presentation on the Duke research at a recent meeting of the American Society of Clinical Oncology.

“In concept, this and many other viral therapies are promising,” Buckner said.

Glioblastoma is the most common and aggressive type of brain cancer and is usually fatal. Standard treatment includes surgery, chemotherapy and radiation, with the tumors reoccurring in 95 percent of cases — nearly 50 percent within eight weeks of treatment.

“We typically expect about a year of survival” after traditional treatment, Desjardins said. “And it really affects who they are, how they function. Mostly it affects people in their late 40s to mid 50s.”

Lipscomb’s case is unusual because she was so young when the tumor developed. Her cancer was discovered after she suffered a series of debilitating headaches in spring 2010, near the end of her freshman year at University of South Carolina-Upstate in Spartanburg.

A brain scan revealed a tennis-ball-sized tumor in her brain just behind her right eye, which was surgically removed in June 2010.

Lipscomb resumed her collegiate life in the spring of 2011, with help from a couple of stylish wigs. But in April 2012, her world was rocked again when she learned the tumor had returned.

Lipscomb immediately agreed when Desjardins offered her the chance to join the poliovirus research effort, even knowing she would be the first patient to enter Phase 1 of the trial.

Her mother, Kelli Lusk, initially had a few reservations. “But it was her decision, her body, and we supported her,” Lusk said.

The procedure was carried out in May of last year and came with few adverse side effects.

Lipscomb’s tumor has so far contracted from the size of a lime to no larger than a green pea.

“That’s awesome,” Lusk said.

Lipscomb is heading back to school this fall, where she has just been accepted into the nursing program. She’s planning to work in oncology after graduation.

Read more Health stories from the Miami Herald

Miami Herald

Join the
Discussion

The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

The Miami Herald uses Facebook's commenting system. You need to log in with a Facebook account in order to comment. If you have questions about commenting with your Facebook account, click here.

Have a news tip? You can send it anonymously. Click here to send us your tip - or - consider joining the Public Insight Network and become a source for The Miami Herald and el Nuevo Herald.

Hide Comments

This affects comments on all stories.

Cancel OK

  • Marketplace

Today's Circulars

  • Quick Job Search

Enter Keyword(s) Enter City Select a State Select a Category